eXoZymes Inc

EXOZ

Market cap $120M

LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process using its proprietary exozyme-based, cell-free biomanufacturing platform. This effort, with a conversion level of over 99% from feedstock to product, marks a major milestone in the scalability of the exozymes platform.

Management to host Q3 2025 update at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - plans to host a webinar at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended October 31, 2025.

LOS ANGELES, CA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced that co-founder of eXoZymes, Tyler Korman, PhD, has taken on the role of Chief Scientific Officer, while Amy Lunzer - an accomplished business, supply-chain, and operations executive - is appointed as Chief of Staff. CSO of eXoZymes, Tyler Korman, PhD, states, "I'm excited to announce that I'm now the Chief Scientific Officer of eXoZymes!

LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 10, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Thursday, November 13, 2025 at 5:00 PM Eastern Time to discuss its results for the third quarter of 2025. Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will be on the 'AI's Billion-dollar Bet on Life Sciences: From Drug Discovery to Patient Impact' panel at Beryl Elites' 7th Annual Investment Conference on November 4, 2025, in New York City. eXoZymes has developed a next gen biomanufacturing platform capable of producing highly valuable natural products.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 29, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will present at the Spartan Capital Securities Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. Participation by eXoZymes underscores the conference's mission to spotlight innovative companies and emerging market leaders positioned for long-term growth.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 23, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will present at the 2025 ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York City. CEO of eXoZymes, Michael Heltzen, states, "Most investors already know that - compared to the number of dollars invested - synthetic biology unfortunately has very little to show for it because it never scaled commercially.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that two of its senior leaders - CCO Damien Perriman and VP of Development, Dr. Paul Opgenorth - have been elected to key roles within the BioMADE Governance Committees. Chief Commercial Officer at eXoZymes, Damien Perriman, states, "Being elected to the BioMADE Leadership Council is both an honor and a responsibility.

Management to host earnings call at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended June 30, 2025.

LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025. Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.